Inncardio Announces Agreement With Sigmoid Biotechnologies

Inncardio, Inc., a company founded by Bioaccelerate Holdings Inc. announced an agreement with Sigmoid Biotechnologies Ltd., based in Dublin, Ireland, for the co-development and license of two novel formulations of established drugs. Upon approval and commercialization, these drugs, which utilize Sigmoid's proprietary delivery and formulation technology, are anticipated to achieve combined peak annual sales of more than $1 billion. Terms of the agreement were not disclosed.

PR Newswire (http://www.prnewswire.com/cgi-bin/stories.pl?ACCT=104&STORY=/www/story/04-18-2005/0003432193&EDATE=)